- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Spyre Therapeutics to Report SPY001 Ulcerative Colitis Trial Results
Biotech firm to host conference call on April 13 to discuss Part A induction topline data from SKYLINE study.
Apr. 13, 2026 at 3:56am
Got story updates? Submit your updates here. ›
Spyre Therapeutics' investigational antibody therapy aims to alleviate the painful inflammation associated with ulcerative colitis.Waltham TodaySpyre Therapeutics, a clinical-stage biotech company focused on inflammatory bowel disease and rheumatic diseases, announced it will report topline results from the Part A induction phase of its SKYLINE trial evaluating SPY001 in moderate-to-severely active ulcerative colitis patients. The company will host a conference call on April 13, 2026 to discuss the findings.
Why it matters
Spyre's SPY001 is a novel long-acting antibody that could potentially redefine the standard of care for ulcerative colitis, a chronic and debilitating form of inflammatory bowel disease. The SKYLINE trial results will be an important milestone in the drug's development and could provide insights into its efficacy and safety profile in this patient population.
The details
The SKYLINE trial is evaluating SPY001, Spyre's investigational extended half-life antibody targeting α4β7, in patients with moderate-to-severely active ulcerative colitis. The Part A induction phase of the study is assessing the drug's safety and efficacy as a standalone therapy. Spyre plans to report the topline results from this portion of the trial on April 13, 2026, followed by a conference call for investors and media.
- Spyre Therapeutics will report SPY001 Part A induction topline results from the SKYLINE trial on Monday, April 13, 2026.
- Spyre will host a conference call and webcast at 8:00am ET on Monday, April 13, 2026 to discuss the results.
The players
Spyre Therapeutics
A clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases.
Eric McIntyre
SVP of Finance and Investor Relations at Spyre Therapeutics.
Josie Butler
Media representative at 1AB, a communications agency.
What’s next
Following the announcement of the Part A induction topline results, Spyre Therapeutics will host a conference call and webcast on April 13, 2026 to discuss the findings in detail.
The takeaway
The upcoming SKYLINE trial results for Spyre's SPY001 in ulcerative colitis patients will be a key milestone in the development of this novel long-acting antibody therapy, which could potentially offer a new treatment option for individuals living with this chronic and debilitating inflammatory bowel disease.
